Status:
ACTIVE_NOT_RECRUITING
Clinico-biological Study/Characterization of Rhabdomyosarcoma in Adolescents and Young Adults, 15-25-year-old Patients
Lead Sponsor:
Centre Oscar Lambret
Collaborating Sponsors:
Centre Leon Berard
Société Française de lutte contre les Cancers et les leucémies de l'Enfant et l'adolescent
Conditions:
Rhabdomyosarcoma
Eligibility:
All Genders
15-25 years
Brief Summary
Rhabdomyosarcoma (RMS) stands for the most frequent soft tissue sarcoma in children and, adolescents and young adults (AYA, 15-25-year-old population), accounting for approximately half of the whole s...
Detailed Description
Rhabdomyosarcoma (RMS) is a rare tumor, with an incidence rate estimated at 4.5-6.9/1,000,000 in paediatric and, adolescent and young adult (AYA, 15 -25 years old) populations. RMS stands for the most...
Eligibility Criteria
Inclusion
- Patients aged from 15 to 25 years old at diagnosis
- Patients registered in EpSSG RMS 2005 trial, or RRePS / NerSarc / Conticabase databases
- Over the period from 2006 to 2014
- Rhabdomyosarcoma histologically proven
- Localized or metastatic
- Histological review and molecular biology available
- No previous treatment except surgery
- No previous cancer
- Absence of known serious chronic illness
- Patient and/or parents information and non-opposition to data collection
Exclusion
- Age over 25 years, or under 15 years
- Other histologies
Key Trial Info
Start Date :
February 2 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2024
Estimated Enrollment :
113 Patients enrolled
Trial Details
Trial ID
NCT03462888
Start Date
February 2 2018
End Date
December 1 2024
Last Update
February 9 2024
Active Locations (20)
Enter a location and click search to find clinical trials sorted by distance.
1
BORDEAUX Bergonié
Bordeaux, France, 33076
2
Bordeaux Chu
Bordeaux, France
3
Brest Chu
Brest, France, 29609
4
LILLE Centre Oscar Lambret/ CHRU de Lille
Lille, France, 59020